Fertility and sterility · 2011
The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-controlled study.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lam Po Mui, Tam Wing Hung, Ma Ronald Ching Wan, Cheung Lai Ping, Tsui Michelle Hang Yuet, Tong Peter Chun Yip, Chow Francis Chun Chung, Lam Christopher Wai Kei, Chan Michael Ho Ming, Chan Juliana Chung Ngor, Haines Christopher John
Аннотация
OBJECTIVE: To investigate whether an insulin sensitizer has any effect on amenorrhea and clinical and biochemical hyperandrogenism in Chinese women with polycystic ovarian syndrome (PCOS).
DESIGN: Randomized controlled double-blind trial.
SETTING: A tertiary referral center, Hong Kong.
PATIENT(S): Chinese women who fulfilled the Rotterdam criteria of PCOS (n = 70).
INTERVENTION(S): Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months.
MAIN OUTCOME MEASURE(S): Menstrual status as well as clinical and biochemical hyperandrogenism.
RESULT(S): There is a significantly higher rate of regular menses among the treatment arm (16 [50.0%] of 32 vs 4 [11.8%] of 34) at 6 months and the improvement appeared to be sustained (10 [41.7%] of 24 vs 6 [20.0%] of 30) at 12 months. There was no change in the acne and hirsutism scores as well as serum T levels in both arms.
CONCLUSION(S): We found a possible benefit in menstrual cyclicity but a lack of improvement in hyperandrogenism in our Chinese population.
CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-09000670 (Chinese Clinical Trial Registry).
DESIGN: Randomized controlled double-blind trial.
SETTING: A tertiary referral center, Hong Kong.
PATIENT(S): Chinese women who fulfilled the Rotterdam criteria of PCOS (n = 70).
INTERVENTION(S): Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months.
MAIN OUTCOME MEASURE(S): Menstrual status as well as clinical and biochemical hyperandrogenism.
RESULT(S): There is a significantly higher rate of regular menses among the treatment arm (16 [50.0%] of 32 vs 4 [11.8%] of 34) at 6 months and the improvement appeared to be sustained (10 [41.7%] of 24 vs 6 [20.0%] of 30) at 12 months. There was no change in the acne and hirsutism scores as well as serum T levels in both arms.
CONCLUSION(S): We found a possible benefit in menstrual cyclicity but a lack of improvement in hyperandrogenism in our Chinese population.
CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-09000670 (Chinese Clinical Trial Registry).